Edition:
United States

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

60.49USD
12:42pm EDT
Change (% chg)

$-0.38 (-0.62%)
Prev Close
$60.87
Open
$61.01
Day's High
$62.40
Day's Low
$60.46
Volume
229,258
Avg. Vol
1,249,593
52-wk High
$111.36
52-wk Low
$22.04

Chart for

About

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and... (more)

Overall

Beta: 2.36
Market Cap(Mil.): $10,498.17
Shares Outstanding(Mil.): 172.47
Dividend: --
Yield (%): --

Financials

  NKTR.OQ Industry Sector
P/E (TTM): 12.44 109.17 32.55
EPS (TTM): 4.89 -- --
ROI: 68.92 1.47 12.80
ROE: 96.87 0.22 14.92

Bristol-Myers cancer ruling hits shares after strong earnings

NEW YORK Bristol-Myers Squibb Co on Thursday said European regulators plan to recommend against approving its immunotherapy combination as an initial treatment for kidney cancer, sending shares lower even after the U.S. drugmaker reported better-than-expected quarterly profit and raised its full-year forecast.

Jul 26 2018

UPDATE 2-Bristol-Myers cancer ruling hits shares after strong earnings

NEW YORK, July 26 Bristol-Myers Squibb Co on Thursday said European regulators plan to recommend against approving its immunotherapy combination as an initial treatment for kidney cancer, sending shares lower even after the U.S. drugmaker reported better-than-expected quarterly profit and raised its full-year forecast.

Jul 26 2018

Bristol-Myers Q2 earnings rise, full-year forecast up on strong sales

NEW YORK, July 26 Bristol-Myers Squibb Co on Thursday posted better-than-expected second-quarter earnings and raised its full-year forecast on strong sales from its blockbuster cancer drug Opdivo and blood thinner Eliquis.

Jul 26 2018

US STOCKS-Tech rally helps Wall St push higher, Nasdaq has record close

* Indexes gain: Dow 0.72 pct, S&P 0.45 pct, Nasdaq 0.69 pct (Updates to close, adds commentary)

Jun 04 2018

US STOCKS-Technology rally helps Wall Street push higher

* Indexes gain: Dow 0.66 pct, S&P 0.41 pct, Nasdaq 0.57 pct (Updates to late afternoon, adds commentary, changes byline, adds New York dateline)

Jun 04 2018

US STOCKS-Tech rally fuels Nasdaq to near record levels

* Indexes gain: Dow 0.76 pct, S&P 0.42 pct, Nasdaq 0.59 pct (Changes comment, adds details, updates prices)

Jun 04 2018

US STOCKS-Wall Street higher as Apple leads tech rally

* Indexes gain: Dow 0.73 pct, S&P 0.27 pct, Nasdaq 0.28 pct (Changes comment, adds details, updates prices)

Jun 04 2018

Mixed results for Bristol/Nektar combination in cancer trial

Chicago, June 3 Mixed results over the weekend from closely watched studies combining Bristol-Myers Squibb Co's cancer immunotherapy with Nektar Therapeutics experimental drug NKTR-214, led at least one Wall Street analyst to reassess expectations.

Jun 03 2018

BRIEF-Nektar Therapeutics Reports Q1 Loss Per Share $0.60

* Q1 EARNINGS PER SHARE VIEW $-0.54 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

May 10 2018

BRIEF-Nektar Therapeutics Says CEO Howard W. Robin's 2017 Total Compensation Was $18.1 Million

* NEKTAR THERAPEUTICS SAYS CEO HOWARD W. ROBIN'S 2017 TOTAL COMPENSATION WAS $18.1 MILLION – SEC FILING

Apr 30 2018

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥4,757 +44.00
Eisai Co., Ltd (4523.T) ¥10,645 +375.00
NOF CORPORATION (4403.T) ¥3,755 +110.00
Dr.Reddy's Laboratories Ltd (REDY.NS) Rs2,611.70 +57.75
Novo Nordisk A/S (NOVOb.CO) kr.306.80 +6.00
Pfizer Inc. (PFE.N) $44.09 +0.16
Novartis AG (NOVN.S) CHF83.18 +1.38
Roche Holding Ltd. (ROG.S) CHF236.15 +3.15
Roche Holding Ltd. (RO.S) CHF237.00 +3.00
GlaxoSmithKline plc (GSK.L) 1,535.20 +12.40

Earnings vs. Estimates